Prilocaine 100mg/20ml solution for injection vials
Requires a prescription from a doctor or prescriber
A local anesthetic that is similar pharmacologically to lidocaine.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Prilocaine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Prilocaine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Prilocaine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 7 · Randomised trials: 36 · 1965–2026
Showing the 50 most relevant studies, sorted by most relevant.
A. Taddio, Arne Ohlsson, Thomas R. Einarson, et al.
Pediatrics, 1998
A. M. Abbas, A. Mohamed, O. Mattar, et al.
The Journal of Maternal-Fetal & Neonatal Medicine, 2018
A. Abbas, Mohamed S. Abdellah, Mohamed Khalaf, et al.
Contraception, 2017
Atousa Akhgar, Amirreza Mazidabadi Farahani, Hamideh Akbari, et al.
Emergency Medicine Journal, 2025
- Pain
- Lidocaine
- Prilocaine
Erfei Zhang, Xiaoying Zhao, Ting-Pei Li, et al.
BMC Anesthesiology, 2023
Bahaa Eldin AM, Abdelkhalek Abdelfattah MM, Asad Farahat OM, et al.
2026
Vats A, Gupta PK, Berrill A, et al.
2025
BackgroundOur trial addresses the gaps in the current literature by directly estimating the ED95 of short-acting local anaesthetics for ultrasound-guided axillary and supraclavicular brachial plexus blocks for surgical anaesthesia.MethodsFour double-blind prospective studies were organized in two separate arms. Patients were randomised between studies A (lidocaine 1% with adrenaline) and B (lidocaine 2% with adrenaline) for axillary blocks and between studies C (prilocaine 1%) and D (lidocaine 1% with adrenaline) for supraclavicular blocks. All statistical modelling and analysis were performed using the modified continual reassessment method. The primary endpoint of the studies was the loss of cold and pin-prick sensations in the sensory distributions of the median, musculocutaneous, radial, and ulnar nerves.ResultsFor axillary blocks, the estimated ED95 of lidocaine 1% with adrenaline was 40 ml (95% credibility interval: 89.5-99.2%), and lidocaine 2% with adrenaline was 15 ml (95% credibility interval: 87.4-97.5%) (studies A and B: 41 and 40 patients, respectively). The ED95 could not be determined for supraclavicular blocks as it fell outside the dose range considered in the studies (studies C and D: 31 and 42 patients, respectively).ConclusionsWe achieved a 95% success rate for axillary blocks using lidocaine (1% and 2%) with adrenaline within our dosing limits. For supraclavicular blocks, >40 ml of prilocaine 1% or lidocaine 1% with adrenaline may be required to consistently achieve a 95% success rate. Our studies highlight the continual reassessment method as a credible methodology for dose-finding studies in regional anaesthesia.Clinical trial registrationEudraCT ref: 2010-018466-22.
Abstract licence: CC BY-NC-ND
Trinder R, Park J, Humm K, et al.
2025
- Lidocaine
- Prilocaine
- Anesthetics, Local
Liu L, Zhang F, Han C, et al.
2026
- Lidocaine
- Prilocaine
- Anesthetics, Local
Franceschi C, Tasso F, Simili V, et al.
2026
- Prilocaine
- Procaine
- Anesthetics, Local
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
1 found
Half-life
Not available
Mechanism
Prilocaine acts on sodium channels on the neuronal cell membrane, limiting the s…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Protein binding
55%
[L39529]
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1619 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L39529]
Proteins and enzymes this drug interacts with in the body
The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:1309946 PMID:21447824 PMID:23085483 PMID:23420830 PMID:25370050 PMID:26279430 PMID:26392562 PMID:26776555
Nav1.5 is the predominant sodium channel expressed in myocardial cells and it is responsible for the initial upstroke of the action potential in cardiac myocytes, thereby initiating the heartbeat .
PMID:11234013 PMID:11804990 PMID:12569159 PMID:1309946
Required for normal electrical conduction including formation of the infranodal ventricular conduction system and normal action potential configuration, as a result of its interaction with XIRP2 (By similarity)
ATC N01BB54
ATC N01BB04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Prilocaine
Additional database identifiers
Drugs Product Database (DPD)
5776
Drugs Product Database (DPD)
9797
ChemSpider
4737
BindingDB
50225477
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10593
GenAtlas
SCN5A
GeneCards
SCN5A
GenBank Gene Database
M77235
GenBank Protein Database
184039
Guide to Pharmacology
582
UniProt Accession
SCN5A_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72